(:TALS)

Oct 17, 2023 05:47 pm ET
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris’ stockholders voted in favor of all proposals, including the...
Oct 06, 2023 05:09 pm ET
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline Bio,...
Oct 04, 2023 08:30 am ET
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain...
Oct 02, 2023 03:55 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating AEL, CPRI, TALS, and PFSW; Shareholders are Encouraged to Contact the Firm
, Oct. 02, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of American Equity Investment Life Holding Company, Capri Holdings Limited, Talaris Therapeutics, Inc., and...
Sep 29, 2023 01:23 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APRN, RENB, TALS, WMC
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 28, 2023 02:47 pm ET
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Therapeutics, Inc. (NasdaqGM: TALS) with Tourmaline Bio, Inc. pursuant to which Talaris shareholders will end up owning approximately 21.3% of the combined company, each on a fully diluted basis. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Aug 21, 2023 05:24 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS, QUOT, NEWR, EMAN
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 14, 2023 06:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – EMAN, QUOT, TALS, NEWR
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 07, 2023 05:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, TALS, NLTX, CCF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Aug 02, 2023 07:48 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, AEL, PACW
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Talaris Therapeutics, Inc. (NASDAQ:...
Aug 01, 2023 07:30 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 01, 2023 03:56 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, TALS, QUOT, CFMS
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 31, 2023 05:32 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS, NETI, WTT, AEL
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 28, 2023 02:21 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INP
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jul 28, 2023 02:17 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Talaris Therapeutics, Inc. (NASDAQ:...
Jul 28, 2023 12:57 pm ET
Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Jul 25, 2023 03:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOT
NEW YORK, July 25, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 24, 2023 08:43 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – NETI, AEL, TALS, WTT
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Jul 18, 2023 10:39 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS
NEW YORK, July 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 17, 2023 05:09 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – AEL, NETI, WTT, TALS
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 16, 2023 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, FREQ, TALS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NASDAQ:...
Jul 15, 2023 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of KLR, CFMS, TALS, and SGTX
Kaleyra, Inc. (NYSE: KLR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash. If you are a KLR investor, and...
Jul 11, 2023 07:38 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, QUOT, TALS, CFMS
NEW YORK, July 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 10, 2023 09:28 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CIR, PDCE, TALS, QUOT
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jun 28, 2023 10:44 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CIR, TALS, CHRA, QUOT
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jun 27, 2023 03:52 am ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI
NEW YORK, June 27, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 26, 2023 04:44 pm ET
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (Nasdaq – TALS)
Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Talaris Therapeutics, Inc. (“Talaris” or the “Company”) (Nasdaq – TALS) for possible breaches of fiduciary duty and other violations...
Jun 25, 2023 08:33 am ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, CFMS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Talaris Therapeutics, Inc. (NASDAQ:...
Jun 24, 2023 09:01 pm ET
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Therapeutics, Inc. (NasdaqGM: TALS) with Tourmaline Bio, Inc. pursuant to which Talaris shareholders will end up owning approximately 21.3% of the combined company, each on a fully diluted basis. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Jun 22, 2023 01:04 pm ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
NEW YORK, June 22, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 22, 2023 09:08 am ET
TALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Talaris Therapeutics, Inc. (NASDAQ: TALS) and Tourmaline Bio, Inc. is fair to Talaris shareholders. Talaris shareholders immediately prior to the proposed transaction are expected to own approximately 21.3% of the combined company.
Jun 22, 2023 07:30 am ET
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) and Tourmaline Bio, Inc. (“Tourmaline”), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune...
May 26, 2023 07:00 am ET
Talaris Therapeutics Announces Leadership Transition
Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief...
Feb 16, 2023 07:00 am ET
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan
Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating...
Nov 22, 2022 07:00 am ET
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Nov 10, 2022 07:00 am ET
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today reported...
Nov 07, 2022 07:00 am ET
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data...
Oct 20, 2022 07:00 am ET
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced a...
Oct 17, 2022 07:00 am ET
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Oct 04, 2022 07:00 am ET
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Sep 21, 2022 07:00 am ET
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Sep 06, 2022 07:00 am ET
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Aug 15, 2022 07:00 am ET
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies...
Jun 30, 2022 07:00 am ET
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff...
Jun 07, 2022 04:01 pm ET
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented...
Jun 01, 2022 07:00 am ET
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it...
May 31, 2022 07:00 am ET
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
May 17, 2022 04:01 pm ET
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
May 17, 2022 07:00 am ET
Talaris Therapeutics Announces Changes to Board of Directors
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
May 12, 2022 04:01 pm ET
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today reported...
May 02, 2022 07:00 am ET
Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Apr 06, 2022 04:01 pm ET
Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today shared new...
Mar 22, 2022 04:01 pm ET
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members...
Mar 17, 2022 04:01 pm ET
Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today reported financial...
Feb 11, 2022 07:00 am ET
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Jan 06, 2022 07:00 am ET
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Jan 04, 2022 07:00 am ET
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced...
Dec 20, 2021 07:00 am ET
Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index
Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Dec 14, 2021 07:00 am ET
Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant
Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA mismatching between donors and recipients participating in the Company’s Phase 2 trial in living donor kidney transplant...
Nov 30, 2021 07:00 am ET
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma
Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Nov 12, 2021 07:00 am ET
Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Nov 08, 2021 07:00 am ET
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Nov 04, 2021 06:00 am ET
Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting
First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with stable kidney functionAll Phase 3 patients who...
Oct 29, 2021 07:00 am ET
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction
Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Oct 28, 2021 04:36 pm ET
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021. In a poster being...
Sep 02, 2021 07:00 am ET
Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Aug 12, 2021 07:00 am ET
Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Jun 14, 2021 04:01 pm ET
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
Jun 03, 2021 07:00 am ET
Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
May 11, 2021 04:01 pm ET
Talaris Therapeutics Announces Closing of Initial Public Offering
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe...
May 06, 2021 09:53 pm ET
Talaris Therapeutics Announces Pricing of Initial Public Offering
Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.